Summit Therapeutics plc Summit To Present On Pipeline And Strategy For Its New Classes Of Antibiotics At Asm Microbe 2019
20 6월 2019 - 8:00PM
UK Regulatory
TIDMSUMM
Summit Therapeutics plc
('Summit' or the 'Company')
Summit to Present on Pipeline and Strategy for its New Classes of
Antibiotics at ASM Microbe 2019
Oxford, UK, and Cambridge, MA, US, 20 June 2019 -- Summit Therapeutics
plc (NASDAQ: SMMT, AIM: SUMM) today announced that it will present on
its pipeline and strategy for the Company's new classes of antibiotics
at the American Society for Microbiology Microbe conference taking place
20-24 June 2019 in San Francisco, CA.
"Developing new classes of antibiotics is critical to the fight against
antimicrobial resistance. One of our new class antibiotics, SMT-571, has
the potential to treat gonorrhoea, an urgent healthcare threat with
increasing numbers of cases alongside the spread of drug resistant
infections. In preclinical data being presented at ASM Microbe, SMT-571
demonstrated the ability to readily kill bacteria which have become
extensively resistant to antibiotics already on the market," said Dr
David Roblin, President of R&D of Summit. "With truly novel antibiotics,
we believe we are well placed to execute development strategies that
have the potential to demonstrate significant advantages over current
standards of care, both in terms of improving patient outcomes and in
reducing healthcare costs."
Details of the presentations are as follows:
Date: 21 June 2019
Time: 2:52-3:03pm PDT
Session: Pharma Pipeline Update: Part I
Location: AAR Track Hub (Booth 5053) -- Learn -- Exhibit and Poster Hall
3
Summary: Summit has a unique three-pronged strategy in infectious
diseases aimed at creating a successful, fully-integrated company. The
Company focuses on new science to discover new classes of antibiotics
targeted to treat specific infections. Summit's pipeline currently
contains late-stage clinical and preclinical programmes for infections
caused by C. difficile, N. gonorrhoeae and Enterobacteriaceae, and the
Company's Discuva Platform enables the expansion of this pipeline.
Summit designs creative development programmes aimed to show significant
advantages over current standards of care. Finally, Summit looks to
achieve commercial success by demonstrating both clinical and economic
advantages of its antibiotics over currently available treatments.
Date: 23 June 2019
Time: 10:30am-4:00pm PDT
Session: New Antimicrobial Agents (pre-phase 2): Inhibitors for Novel
Targets (1)
Location: Exhibit and Poster Hall P589
Title:
https://www.globenewswire.com/Tracker?data=bQhFykQxlAbHrPJp7e2toqNmRn4Jd0RK20yiRx3xPDSRmsgg-9mpj1HVcx8pg24VA7ESPvfiycjm6i2P-V8P1cEar7HidBMzdE412srMfOk07yemKOiy0XQlZ395bDjW-noBlXlIU2KdQXWEKnL8yLVYuQH2-Lc3o5hl56zqMc6Kxu0wxVZUPJ_Hq0aAWcTh4DbZBzMg74s90fu2R0APXlYjr9nzNrFaAI8-fCoupX2HRzUttobL-Fa97II3BD2jNhUgLzeC3KCKGtULcHbFfA9GxXC4pfecKitnZCzXwh4=
In Vitro Activity of SMT-571 and Comparators against Clinical Isolates
and Reference Strains of Neisseria gonorrhoeae
Authors: P. Meo, C. Mason, N. Khan, of Summit Therapeutics and M. Unemo
and S. Jacobsson of Örebro University
Summary: Preclinical data showed SMT-571 to be highly potent against 262
clinical strains of N. gonorrhoeae. This comprehensive panel of
gonorrhoea strains, obtained from 1991 to 2018, was designed to be
geographically and genetically diverse and include strains that are
extensively- and multi-drug resistant, including ones resistant to
ceftriaxone, the current standard of care for gonorrhoea. SMT-571, which
works by a new mechanism of action targeting cell-division, was shown to
be equally potent against all strains tested. It had a minimum
inhibitory concentration of 0.064 to 0.125 mg/L against the strains,
including those that are not susceptible to ceftriaxone. Significantly,
SMT-571 did not show cross-resistance with any antibiotic currently or
previously used to treat gonorrhoea infections.
A copy of the presentations will be available at the start of the
sessions in the Publications section of the Company's website:
https://www.globenewswire.com/Tracker?data=RQjk8auYt7mmLShaPk9jyWzzOeiM_Jx_5uk-yrfFE-5CsWn9D0Zsvsb7ilpXjdlskN893kvhPPyXyvb5KwlO7Rx-G9kUZak1-SlYxkXRmgg=
www.summitplc.com.
About Gonorrhoea
It is estimated by the World Health Organization ('WHO') that there are
approximately 78 million new cases of gonorrhoea globally per year.
Neisseria gonorrhoeae has consistently developed resistance to each
class of antibiotics recommended for treatment and there is now only one
treatment recommended by the CDC and European evidence-based guidelines,
a combination of two antibiotics. There are currently no other
recommended antibiotics that can be effectively deployed to target the
disease. The WHO ranks as "High" the priority of R&D investment into the
search for antibiotics which are effective against N. gonorrhoeae and in
August 2018, the CDC stated that in light of increased problems with
resistance, additional treatment options were urgently required.
About SMT-571
SMT-571 is a small molecule, novel mechanism antibiotic in preclinical
development for the treatment of gonorrhoea. SMT-571 is designed to be
an oral treatment with potential activity across the three sites of
gonorrhea infection: urogenital, rectal and pharyngeal. Preclinical
studies have shown SMT-571 to have potent activity across a wide range
of N. gonorrhoeae strains, including multi- and extensively-drug
resistant ones. SMT-571 was identified using Summit's Discuva Platform,
which can identify novel targets, elucidate mechanisms of action and
optimise against bacterial resistance.
The development of SMT-571 is supported by the Cooperative Agreement
Number IDSEP160030 from ASPR/BARDA and by an award from Wellcome Trust,
as administered by CARB-X. The content of this announcement is solely
the responsibility of the authors and does not necessarily represent the
official views of the Department of Health and Human Services Office of
the Assistant Secretary for Preparedness and Response, other funders, or
CARB-X.
About Summit Therapeutics
Summit Therapeutics is a leader in antibiotic innovation. Our new
mechanism antibiotics are designed to become the new standards of care
for the benefit of patients and create value for payors and healthcare
providers. We are currently developing new mechanism antibiotics for
infections caused by C. difficile, N. gonorrhoeae and Enterobacteriaceae
and are using our proprietary Discuva Platform to expand our pipeline.
For more information, visit www.summitplc.com and follow us on Twitter
@summitplc.
Contacts
Summit
Glyn Edwards / Richard Pye (UK office) Tel: 44 (0)1235 443 951
Michelle Avery (US office) +1 617 225 4455
Cairn Financial Advisers LLP (Nominated
Adviser) Tel: +44 (0)20 7213 0880
Liam Murray / Tony Rawlinson
N+1 Singer (Joint Broker) Tel: +44 (0)20 7496 3000
Aubrey Powell / Jen Boorer, Corporate
Finance
Tom Salvesen, Corporate Broking
Bryan Garnier & Co Limited (Joint
Broker) Tel: +44 (0)20 7332 2500
Phil Walker / Dominic Wilson
MSL Group (US) Tel: +1 781 684 6557
mailto:summit@mslgroup.com
Jon Siegal summit@mslgroup.com
---------------------------------
Consilium Strategic Communications (UK) Tel: +44 (0)20 3709 5700
Mary-Jane Elliott / Sue Stuart / mailto:summit@consilium-comms.com
summit@consilium-comms.com
---------------------------------
Lindsey Neville
Summit Forward-looking Statements
Any statements in this press release about the Company's future
expectations, plans and prospects, including but not limited to,
statements about the clinical and preclinical development of the
Company's product candidates, the therapeutic potential of the Company's
product candidates, the potential commercialisation of the Company's
product candidates, the sufficiency of the Company's cash resources, the
timing of initiation, completion and availability of data from clinical
trials, the potential submission of applications for marketing approvals
and other statements containing the words "anticipate," "believe,"
"continue," "could," "estimate," "expect," "intend," "may," "plan,"
"potential," "predict," "project," "should," "target," "would," and
similar expressions, constitute forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995. Actual
results may differ materially from those indicated by such
forward-looking statements as a result of various important factors,
including: the uncertainties inherent in the initiation of future
clinical trials, availability and timing of data from ongoing and future
clinical trials and the results of such trials, whether preliminary
results from a clinical trial will be predictive of the final results of
that trial or whether results of early clinical trials or preclinical
studies will be indicative of the results of later clinical trials,
expectations for regulatory approvals, laws and regulations affecting
government contracts and funding awards, availability of funding
sufficient for the Company's foreseeable and unforeseeable operating
expenses and capital expenditure requirements and other factors
discussed in the "Risk Factors" section of filings that the Company
makes with the Securities and Exchange Commission, including the
Company's Annual Report on Form 20-F for the fiscal year ended 31
January 2019. Accordingly, readers should not place undue reliance on
forward-looking statements or information. In addition, any
forward-looking statements included in this press release represent the
Company's views only as of the date of this release and should not be
relied upon as representing the Company's views as of any subsequent
date. The Company specifically disclaims any obligation to update any
forward-looking statements included in this press release.
-END-
(END) Dow Jones Newswires
June 20, 2019 07:00 ET (11:00 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Summit Therapeutics (LSE:SUMM)
과거 데이터 주식 차트
부터 12월(12) 2024 으로 1월(1) 2025
Summit Therapeutics (LSE:SUMM)
과거 데이터 주식 차트
부터 1월(1) 2024 으로 1월(1) 2025
